Medizinische Universität Graz - Research portal
Selected Publication:
Petru, E; Schmähl, D.
Cytotoxic chemotherapy-induced second primary neoplasms: clinical aspects.
Neoplasma. 1991; 38(2):147-155
Web of Science
PubMed
Google Scholar
- Leading authors Med Uni Graz
- Petru Edgar
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- The incidence of second malignancies was assessed by retrospectively analyzing data from previous studies in well-defined and closely followed patient cohorts. After a median follow-up of more than 6 years following MOPP (mechlorethamine/vincristine/procarbazine/prednisone) chemotherapy with or without radiotherapy, 5% of patients with Hodgkin's disease developed second primaries, 60% of which were leukemias. Melphalan caused a 3% leukemia rate among 1129 patients with ovarian cancer who were followed for a median period of 4 years. No leukemia was observed among 1132 breast cancer patients treated with adjuvant CMF (cyclophosphamide/methotrexate/5-fluorouracil) after a median follow-up of 7.5 years. Long-term, comprehensive studies are needed to improve the current knowledge and the prognosis of patients with second primary neoplasms.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Agents - adverse effects
- Antineoplastic Combined Chemotherapy Protocols - adverse effects
- Breast Neoplasms - drug therapy
- Female - drug therapy
- Hodgkin Disease - drug therapy
- Humans - drug therapy
- Leukemia - chemically induced
- Mechlorethamine - administration and dosage
- Melphalan - adverse effects
- Neoplasms, Multiple Primary - epidemiology
- Ovarian Neoplasms - drug therapy
- Prednisone - administration and dosage
- Procarbazine - administration and dosage
- Randomized Controlled Trials - administration and dosage
- Retrospective Studies - administration and dosage
- Vincristine - administration and dosage
- Find related publications in this database (Keywords)
- Chemotherapy
- 2nd Neoplasms
- Toxicity
- Long-Term Effects